Items where Author is "Muth, J"

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 5.

Journal article

VADAKEKOLATHU NARAYANAN, J., MINDEN, M.D., HOOD, T., CHURCH, S.E., REEDER, S., ALTMANN, H., SULLIVAN, A.H., VIBOCH, E.J., PATEL, T., IBRAHIMOVA, N., WARREN, S.E., ARRUDA, A., LIANG, Y., SMITH, T.H., FOULDS, G.A., BAILEY, M.D., GOWEN-MACDONALD, J., MUTH, J., SCHMITZ, M., POCKLEY, A.G., CESANO, A., VALK, P.J.M., LÖWENBERG, B., BORNHÄUSER, M., TASIAN, S.K., RETTIG, M.P., DAVIDSON-MONCADA, J., DIPERSIO, J.F. and RUTELLA, S., 2020. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Science Translational Medicine, 12 (546): eaaz0463. ISSN 1946-6234

PARK, H., URONIS, H., KANG, Y., NG, M.C.H., ENZINGER, P., LEE, K.W., RUTELLA, S., CHURCH, S.E., NORDSTROM, J., KNUTSON, K., ERSKINE, C., WU, T., YEN, J., FRANOVIC, A., MUTH, J., ROSALES, M., VADAKEKOLATHU, J., DAVIDSON-MONCADA, J., BANG, Y. and CATENACCI, D.V., 2019. Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T). Annals of Oncology, 30 (Supp5), v485. ISSN 0923-7534

RUTELLA, S., CHURCH, S.E., VADAKEKOLATHU, J., REEDER, S., SULLIVAN, A.H., WARREN, S., BAUGHMAN, J., MUTH, J., PARK, H., URONIS, H., KANG, Y., NG, M.C.H., ENZINGER, P., LEE, K.W., HUBER, K., WYNTER-HORTON, A., LI, D., BANG, Y., DAVIDSON-MONCADA, J. and CATENACCI, D.V., 2019. Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA). Annals of Oncology, 30 (Supp5), v38-v39. ISSN 0923-7534

RUTELLA, S., CHURCH, S.E., VADAKEKOLATHU, J., VIBOCH, E., SULLIVAN, A.H., HOOD, T., WARREN, S.E., CESANO, A., LA MOTTE-MOHS, R., MUTH, J., LELIÈVRE, H., LOWENBERG, B., DIPERSIO, J.F. and DAVIDSON-MONCADA, J.K., 2018. Adaptive immune gene signatures correlate with response to flotetuzumab, a CD123 × CD3 bispecific Dart® molecule, in patients with relapsed/refractory acute myeloid leukemia. Blood, 132 (S1): 444. ISSN 0006-4971

UY, G.L., RETTIG, M.P., VEY, N., GODWIN, J., FOSTER, M.C., RIZZIERI, D.A., ARELLANO, M.L., TOPP, M.S., HULS, G., JONGEN-LAVRENCIC, M., MARTINELLI, G., PAOLINI, S., CICERI, F., CARRABBA, M.G., SWEET, K.L., RAVANDI, F., CHURCH, S.E., VADAKEKOLATHU, J., RUTELLA, S., SUN, J., YANG, K., BAUGHMAN, J., CURTIS, T., TIMMENY, E., CALI, K., TRAN, K., MUTH, J., LA MOTTE-MOHS, R., POIROT, C., PALLIS, A., CESANO, A., BONVINI, E., WIGGINGTON, J., LOWENBERG, B., DAVIDSON-MONCADA, J.K. and DIPERSIO, J.F., 2018. Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood, 132 (S1): 764. ISSN 0006-4971

This list was generated on Tue Aug 11 00:34:36 2020 UTC.